US Stock Market Move | SpyGlass Pharma (SGP.US) debuted on the US stock market with a opening surge of over 43%.

On Friday, SpyGlass Pharma (SGP.US) made its debut on the US stock market, with its stock price soaring over 43% to $23 at the opening, compared to the IPO price of $16. SpyGlass Pharma is a late-stage biotechnology company focused on developing sustained drug delivery systems for chronic eye diseases, aiming to improve patients' vision and quality of life through longer-lasting and sustainable treatment options. Its core development product includes a system that combines a drug delivery pad with an artificial crystalline lens, used to treat chronic eye conditions such as open-angle glaucoma or high eye pressure. These treatments aim to enhance efficacy and patient compliance, potentially offering advantages over traditional daily eye drops.